☆ 4.8 Editorial Material

Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?

CIRCULATION (2022)

Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers A Multinational Cohort Study

RuiJun Chen et al.

Summary: In a large-scale observational study, it was found that ARBs do not significantly differ in effectiveness compared to ACE inhibitors as first-line treatment for hypertension, but present a better safety profile. This supports the preferential prescription of ARBs over ACE inhibitors when initiating treatment for hypertension.

HYPERTENSION (2021)

添加到收藏夹

Article Medicine, General & Internal